Therapies in early development for the treatment of opiate addiction (Q38594606)

4 September 2017

title

Therapies in early development for the treatment of opiate addiction (English)

1 reference

4 September 2017

author name string

Marta Rodríguez-Arias

series ordinal

1

1 reference

4 September 2017

María A Aguilar

series ordinal

2

1 reference

4 September 2017

José Miñarro

series ordinal

3

1 reference

4 September 2017

language of work or name

English

0 references

publication date

28 September 2015

1 reference

Expert Opinion on Investigational Drugs

4 September 2017

published in

1 reference

4 September 2017

volume

24

1 reference

4 September 2017

issue

11

1 reference

4 September 2017

page(s)

1459-1472

1 reference

Impact of lifetime opioid exposure on arterial stiffness and vascular age: cross-sectional and longitudinal studies in men and women

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

The multi-site prescription opioid addiction treatment study: 18-month outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Addiction and the brain antireward system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Reduction in arterial stiffness and vascular age by naltrexone-induced interruption of opiate agonism: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Heroin-dependent inmates' experiences with buprenorphine or methadone maintenance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble-films

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

A population pharmacokinetic and pharmacodynamic modelling approach to support the clinical development of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid dependenc

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Pharmaceutical and pharmacokinetic characterization of a novel sublingual buprenorphine/naloxone tablet formulation in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Efficacy of extended-release tramadol for treatment of prescription opioid withdrawal: a two-phase randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Injectable and implantable sustained release naltrexone in the treatment of opioid addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

A systematic review and meta-analysis of naltrexone implants for the treatment of opioid dependence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Naltrexone: a review of existing sustained drug delivery systems and emerging nano-based systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Understanding opioid reward

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Ventral tegmental area GABA neurons and opiate motivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Cocaine inverts rules for synaptic plasticity of glutamate transmission in the ventral tegmental area

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Region-specific changes in the subcellular distribution of AMPA receptor GluR1 subunit in the rat ventral tegmental area after acute or chronic morphine administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Epigenetic upregulation of PSD-95 contributes to the rewarding behavior by morphine conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Rationale in support of the use of selective dopamine D₃ receptor antagonists for the pharmacotherapeutic management of substance use disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

The antipsychotic aripiprazole selectively prevents the stimulant and rewarding effects of morphine in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Low dose risperidone attenuates cue-induced but not heroin-induced reinstatement of heroin seeking in an animal model of relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Effect of baclofen on morphine-induced conditioned place preference, extinction, and stress-induced reinstatement in chronically stressed mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Randomized, placebo-controlled pilot trial of gabapentin during an outpatient, buprenorphine-assisted detoxification procedure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Pregabalin role in inhibition of morphine analgesic tolerance and physical dependency in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Neural and psychological mechanisms underlying compulsive drug seeking habits and drug memories--indications for novel treatments of addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Hippocampal long-term potentiation is disrupted during expression and extinction but is restored after reinstatement of morphine place preference

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Synaptic glutamate spillover due to impaired glutamate uptake mediates heroin relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

N-methyl-D-aspartate receptors involved in morphine-induced hyperalgesia in sensitized mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Dorsal hippocampal NMDA receptor blockade impairs extinction of naloxone-precipitated conditioned place aversion in acute morphine-treated rats by suppressing ERK and CREB phosphorylation in the basolateral amygdala

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Increased small conductance calcium-activated potassium type 2 channel-mediated negative feedback on N-methyl-D-aspartate receptors impairs synaptic plasticity following context-dependent sensitization to morphine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Effects of ifenprodil on morphine-induced conditioned place preference and spatial learning and memory in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

NR2B subunit of NMDA receptor at nucleus accumbens is involved in morphine rewarding effect by siRNA study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

A placebo-controlled trial of memantine as an adjunct to injectable extended-release naltrexone for opioid dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Altered phosphorylation of GluA1 in the striatum is associated with locomotor sensitization induced by exposure to increasing doses of morphine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

The mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) potentiates conditioned place preference induced by various addictive and non-addictive drugs in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

AMN082, a metabotropic glutamate receptor 7 allosteric agonist, attenuates locomotor sensitization and cross-sensitization induced by cocaine and morphine in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Involvement of the insular nitric oxide signaling pathway in the expression of morphine-induced conditioned place preference in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Nitric oxide in central amygdala potentiates expression of conditioned withdrawal induced by morphine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Ellagic acid enhances morphine analgesia and attenuates the development of morphine tolerance and dependence in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Cannabidiol inhibits the reward-facilitating effect of morphine: involvement of 5-HT1A receptors in the dorsal raphe nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Interactions between μ-opioid receptor agonists and cannabinoid receptor agonists in rhesus monkeys: antinociception, drug discrimination, and drug self-administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

The α3β4* nicotinic ACh receptor subtype mediates physical dependence to morphine: mouse and human studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Varenicline for opioid withdrawal in patients with chronic pain: a randomized, single-blinded, placebo controlled pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Influence of cholinesterase inhibitors, donepezil and rivastigmine on the acquisition, expression, and reinstatement of morphine-induced conditioned place preference in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Associations between basal cortisol levels and memory retrieval in healthy young individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

The neurokinin-1 receptor in addictive processes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Opioid-like effects of the neurokinin 1 antagonist aprepitant in patients maintained on and briefly withdrawn from methadone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Association between gene variants and response to buprenorphine maintenance treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Epigenetics of drug abuse: predisposition or response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Ethnic diversity of DNA methylation in the OPRM1 promoter region in lymphocytes of heroin addicts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Effect of chronic heroin and cocaine administration on global DNA methylation in brain and liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Epigenetically modified nucleotides in chronic heroin and cocaine treated mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Epigenetic basis of opiate suppression of Bdnf gene expression in the ventral tegmental area

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Differential Changes in Expression of Stress- and Metabolic-Related Neuropeptides in the Rat Hypothalamus during Morphine Dependence and Withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Relationship between vulnerability to reinforcing effects of morphine and activity of the endogenous cholecystokinin system in Lewis and Fischer rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Chronic CRF1 receptor blockade reduces heroin intake escalation and dependence-induced hyperalgesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Corticotropin-releasing factor (CRF) and α 2 adrenergic receptors mediate heroin withdrawal-potentiated startle in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Corticotropin-releasing factor (CRF) receptor-1 is involved in cardiac noradrenergic activity observed during naloxone-precipitated morphine withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Cardiac adverse effects of naloxone-precipitated morphine withdrawal on right ventricle: role of corticotropin-releasing factor (CRF) 1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

The corticotropin-releasing factor receptor-2 mediates the motivational effect of opiate withdrawal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Involvement of neuropeptide FF receptors in neuroadaptive responses to acute and chronic opiate treatments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Morphine dependence is associated with changes in neuropeptide S receptor expression and function in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Neuropeptide trefoil factor 3 attenuates naloxone-precipitated withdrawal in morphine-dependent mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

NPY mediates reward activity of morphine, via NPY Y1 receptors, in the nucleus accumbens shell.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

The NK1 receptor antagonist L822429 reduces heroin reinforcement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Effects of the NOP agonist SCH221510 on producing and attenuating reinforcing effects as measured by drug self-administration in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Obestatin prevents analgesic tolerance to morphine and reverses the effects of mild morphine withdrawal in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Lateral hypothalamic orexin/hypocretin neurons that project to ventral tegmental area are differentially activated with morphine preference

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Hypocretin receptor 2 antagonism dose-dependently reduces escalated heroin self-administration in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

The differential effects of OX1R and OX2R selective antagonists on morphine conditioned place preference in naïve versus morphine-dependent mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Blockade of orexin-1 receptors in the ventral tegmental area could attenuate the lateral hypothalamic stimulation-induced potentiation of rewarding properties of morphine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Orexin type 1 receptor antagonism in Lateral Paragigantocellularis nucleus attenuates naloxone precipitated morphine withdrawal symptoms in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

The oxytocin analogue carbetocin prevents emotional impairment and stress-induced reinstatement of opioid-seeking in morphine-abstinent mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

CCL5 and cytokine expression in the rat brain: differential modulation by chronic morphine and morphine withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Transient receptor potential vanilloid type 1 channel may modulate opioid reward

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Hydrogen sulfide attenuates opioid dependence by suppression of adenylate cyclase/cAMP pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Opioid withdrawal increases transient receptor potential vanilloid 1 activity in a protein kinase A-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Effect of chronic delivery of the Toll-like receptor 4 antagonist (+)-naltrexone on incubation of heroin craving.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Toll-like receptor 4 mutant and null mice retain morphine-induced tolerance, hyperalgesia, and physical dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

Pioglitazone potentiates development of morphine-dependence in mice: possible role of NO/cGMP pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

PPARγ activation attenuates opioid consumption and modulates mesolimbic dopamine transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1086746

10.1517/13543784.2015.1086746

21 January 2018

Identifiers

DOI

1 reference

4 September 2017

1 reference